Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs SP 420 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Sideris Pharmaceuticals
- 01 Dec 2017 Results published in the American Journal of Hematology
- 28 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 04 Sep 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov record.